Lesson plan

Methylone

Methylone, also known as 3,4-methylenedioxy-N-methylcathinone (MDMC), is an entactogen and stimulant drug of the amphetamine, cathinone, and MDxx families related to 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). It is the β-keto or cathinone analogue of MDMA. The drug is usually taken orally, but can also be administered by other routes. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The drug has much less activity at the vesicular monoamine transporter 2 (VMAT2) than MDMA and may have less serotonergic neurotoxicity. In contrast to certain other entactogens like MDMA, methylone does not appear to be a significant agonist of the serotonin 5-HT 2 receptors. Methylone is similar in its effects to MDMA, producing entactogenic effects and euphoria, but has a reputation of being gentler than MDMA and only lasts about half as long. Side effects of methylone include tachycardia, hangover, and insomnia. It may have reduced negative after-effects compared to MDMA. Methylone's onset is about 0.5 hours and its duration is about 2 to 3 hours. Methylone was first synthesized by Peyton Jacob III and Alexander Shulgin in the mid-1990s and was first described in the literature in 1996. It was patented by Jacob and Shulgin as a potential antidepressant and antiparkinsonian agent, but was never developed or marketed for such uses.…

Back to article

Article summary

Methylone, also known as 3,4-methylenedioxy-N-methylcathinone (MDMC), is an entactogen and stimulant drug of the amphetamine, cathinone, and MDxx families related to 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy"). It is the β-keto or cathinone analogue of MDMA. The drug is usually taken orally, but can also be administered by other routes. It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The drug has much less activity at the vesicular monoamine transporter 2 (VMAT2) than MDMA and may have less serotonergic neurotoxicity. In contrast to certain other entactogens like MDMA, methylone does not appear to be a significant agonist of the serotonin 5-HT 2 receptors. Methylone is similar in its effects to MDMA, producing entactogenic effects and euphoria, but has a reputation of being gentler than MDMA and only lasts about half as long. Side effects of methylone include tachycardia, hangover, and insomnia. It may have reduced negative after-effects compared to MDMA. Methylone's onset is about 0.5 hours and its duration is about 2 to 3 hours. Methylone was first synthesized by Peyton Jacob III and Alexander Shulgin in the mid-1990s and was first described in the literature in 1996. It was patented by Jacob and Shulgin as a potential antidepressant and antiparkinsonian agent, but was never developed or marketed for such uses.…

Key claims

  1. publication date: 2010 — source: Wikipedia · confidence 0.95

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. The record states that the publication date is "2010". What evidence would count against this claim?
  3. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  4. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

  1. Wikipedia https://en.wikipedia.org/w/index.php?oldid=1376760575

Key claims and bibliography are generated from the same tracked claims and sources as the article page.